
Array BioPharma Inc. (Nasdaq: ARRY) announced that its Chief Medical Officer, John Yates, M.D., presented additional positive results from a Phase 2 clinical trial evaluating the efficacy of ARRY-797, a novel small molecule pan-cytokine inhibitor, in patients with post-surgical dental pain at the American Pain Society's 27th Annual Scientific Meeting in Tampa, Florida.
Click here for full Story http://www.medicalnewstoday.com/articles/106824.php |